Bio-Thera Solutions, Ltd. — Investor Relations & Filings
About Bio-Thera Solutions, Ltd.
Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 百奥泰 关于参加广东辖区2024年投资者网上集体接待日活动的公告 | 2024-09-09 | Chinese | |
| 百奥泰 关于参加2024年半年度科创板制药及生物制品专场集体业绩说明会的公告 | 2024-09-09 | Chinese | |
| 百奥泰 自愿披露关于度普利尤单抗注射液（BAT2406）获得药物临床试验批准通知书的公告 | 2024-08-30 | Chinese | |
| 百奥泰 自愿披露关于BAT8006联合贝伐珠单抗获得药物临床试验批准通知书的公告 | 2024-08-27 | Chinese | |
| 百奥泰 第二届监事会第十五次会议决议的公告 | 2024-08-22 | Chinese | |
| 百奥泰 关于公司2024年度提质增效重回报专项行动方案的半年度评估报告 | 2024-08-22 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2024
15 filings
| |||||
| 39229352 | 百奥泰 关于参加广东辖区2024年投资者网上集体接待日活动的公告 | 2024-09-09 | Chinese | ||
| 39229342 | 百奥泰 关于参加2024年半年度科创板制药及生物制品专场集体业绩说明会的公告 | 2024-09-09 | Chinese | ||
| 39229331 | 百奥泰 自愿披露关于度普利尤单抗注射液（BAT2406）获得药物临床试验批准通知书的公告 | 2024-08-30 | Chinese | ||
| 39229317 | 百奥泰 自愿披露关于BAT8006联合贝伐珠单抗获得药物临床试验批准通知书的公告 | 2024-08-27 | Chinese | ||
| 39229307 | 百奥泰 第二届监事会第十五次会议决议的公告 | 2024-08-22 | Chinese | ||
| 39229294 | 百奥泰 关于公司2024年度提质增效重回报专项行动方案的半年度评估报告 | 2024-08-22 | Chinese | ||
| 39229281 | 中国国际金融股份有限公司关于百奥泰生物制药股份有限公司使用部分闲置募集资金暂时补充流动资金的核查意见 | 2024-08-22 | Chinese | ||
| 39229273 | 百奥泰 2024年半年度募集资金存放与实际使用情况的专项报告 | 2024-08-22 | Chinese | ||
| 39229262 | 百奥泰 2024年半年度报告 | 2024-08-22 | Chinese | ||
| 39229132 | 百奥泰 2024年半年度报告摘要 | 2024-08-22 | Chinese | ||
| 39229118 | 百奥泰 关于使用部分闲置募集资金暂时补充流动资金的公告 | 2024-08-22 | Chinese | ||
| 39229106 | 百奥泰 关于归还暂时用于补充流动资金的闲置募集资金的公告 | 2024-08-21 | Chinese | ||
| 39229092 | 百奥泰 关于Avzivi（贝伐珠单抗注射液）获欧盟委员会上市批准的公告 | 2024-07-30 | Chinese | ||
| 39229080 | 百奥泰 2024年半年度业绩预告的自愿性披露公告 | 2024-07-29 | Chinese | ||
| 39229069 | 百奥泰 自愿披露关于与Hikma Pharmaceuticals USA Inc.就BAT2206（乌司奴单抗）注射液签署授权许可与商业化协议收到里程碑付款的公告 | 2024-07-24 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Bio-Thera Solutions, Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/58210/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=58210 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=58210 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=58210 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 58210}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Bio-Thera Solutions, Ltd. (id: 58210)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.